07:26 AM EDT, 05/02/2024 (MT Newswires) -- Moderna ( MRNA ) reported a Q1 loss Thursday of $3.07 per diluted share, swinging from earnings of $0.19 a year earlier.

Analysts polled by Capital IQ expected a loss of $3.57.

Revenue for the quarter ended March 31 was $167 million, down from $1.86 billion a year earlier.

Analysts surveyed by Capital IQ expected $125.3 million.

The pharmaceutical company affirmed its previous revenue guidance of $300 million in H1 and $4 billion for 2024 on sales of its respiratory infections vaccines. Analysts polled by Capital IQ expect Q2 revenue of $72.2 million and full-year revenue of $4.21 billion.